# Sung-Bae Kim

Source: https://onco.cc/people/kim-sung-bae/  
OnCo record `kim-sung-bae` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sung-Bae Kim is a leading Korean breast oncologist on the steering committees of the trastuzumab emtansine and deruxtecan trials.

## Summary

Sung-Bae Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in breast cancer. He is a leading Korean breast oncologist who sits on the steering committees of the trastuzumab emtansine and trastuzumab deruxtecan trials, and has been an investigator on many pivotal HER2-positive and triple-negative breast cancer studies, including EMILIA, the DESTINY-Breast trials and immunotherapy combinations. His publications include the DESTINY-Breast03 trial comparing trastuzumab deruxtecan with trastuzumab emtansine in HER2-positive metastatic breast cancer. He co-leads Korean breast cancer research networks, with interests in HER2-positive disease and antibody-drug conjugates.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; breast cancer
- Specialisms: Breast cancer; HER2-positive disease; Triple-negative breast cancer; Antibody-drug conjugates

## Sources

- Asan Medical Center: https://eng.amc.seoul.kr
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [Asan Medical Center](https://onco.cc/institutions/asan-medical-center/)
- trials: [DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/)
- key papers: [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial](https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/), [Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy](https://onco.cc/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/)

---
JSON: https://onco.cc/api/v1/entities/kim-sung-bae.json